Akeso Receives Positive News for Ivonescimab Approval
Akeso, Inc. (9926.HK) is excited to share that the National Medical Products Administration (NMPA) has accepted the supplementary New Drug Application (sNDA) for ivonescimab. This remarkable treatment is being evaluated in combination with chemotherapy as a first-line therapy for advanced squamous non-small cell lung cancer (sq-NSCLC).
Significance of the Application
This acceptance marks the third application for ivonescimab in recent months, following previous submissions for its use in combination therapy for EGFR-TKI resistant locally advanced or metastatic non-squamous NSCLC, and its monotherapy for first-line treatment of PD-L1 positive advanced NSCLC. The progress in these applications showcases the commitment of Akeso to advancing cancer treatments and improving patient outcomes.
Strong Clinical Evidence
The sNDA is largely supported by robust data from the Phase III trial (AK112-306/HARMONi-6 study), which demonstrated that ivonescimab combined with chemotherapy outperforms tislelizumab paired with chemotherapy. This evidence emphasizes ivonescimab as a leading candidate in the evolving landscape of global cancer immunotherapy, showcasing its superior efficacy in providing better treatment options for patients.
Extensive Clinical Trials and Applications
Ivonescimab is currently involved in over 12 registrational/Phase III clinical trials around the world, including six head-to-head studies comparing it with PD-1/L1 inhibitors. These trials encompass a variety of malignant conditions, including different lung cancer subtypes, colorectal cancer, head and neck squamous cell carcinoma, biliary tract cancer, pancreatic cancer, and triple-negative breast cancer, demonstrating its broad applicability and strategic potential in cancer therapies.
Innovative Treatment Strategies
As a strategic part of the company's "IO+ADC" 2.0 oncology strategy, ivonescimab is positioned as a cornerstone in immuno-oncology. Akeso is currently exploring innovative treatment combinations that could pioneer new pathways in the treatment of cancers. This focus on combination therapies highlights the company's dedication to not only advancing drug efficacy but also enhancing patient care.
About Akeso
Akeso, established in 2012, has swiftly emerged as a prominent biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative biological medicines. Central to its mission is the creation of unique solutions utilizing an integrated R&D system supported by a comprehensive drug development platform and cutting-edge bi-specific antibody technology. Currently, Akeso maintains a diverse pipeline of over 50 innovative assets targeting various diseases, with 24 of these candidates actively in clinical trials. The company is committed to delivering groundbreaking therapies that meet the needs of patients globally.
Frequently Asked Questions
What is ivonescimab used for?
Ivonescimab is used in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer.
Which organization accepted the sNDA for ivonescimab?
The National Medical Products Administration (NMPA) accepted the supplementary New Drug Application for ivonescimab.
What are the potential benefits of ivonescimab?
Ivonescimab has shown superior efficacy compared to other treatments in clinical trials, potentially offering better outcomes for patients with advanced lung cancer.
How many clinical trials is ivonescimab currently involved in?
Ivonescimab is involved in over 12 registrational and Phase III clinical trials worldwide.
What is Akeso's commitment in biopharmaceuticals?
Akeso is committed to developing innovative biological medicines focusing on improving patient care and providing effective therapeutic solutions.
